Governance Kyverna Therapeutics, Inc.

KYTX

US5019761049

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-05 pm EST			5-day change	1st Jan Change
8.390 ^USD	-5.41%		+3.33%	-10.74%

Feb. 24	Kyverna Therapeutics, Inc. Announces Board and Committee Changes	CI
Feb. 24	Kyverna Therapeutics appoints biotech leaders Sravan Emany and Andrew Miller to board of directors	RE

Executive Committee: Kyverna Therapeutics, Inc.

Manager

Positions heldSince

Warner Biddle

59 year

Chief Executive Officer

2024-09-15

Marc Grasso

53 year

Comptroller/Controller/Auditor	2025-06-29
Director of Finance/CFO	2025-06-29

Mayo Pujols

57 year

Chief Tech/Sci/R&D Officer

2026-02-08

Tracy Rossin

48 year

Investor Relations Contact	2024-12-12
Public Communications Contact	2024-12-12

Cara Bauer

Human Resources Officer

2024-12-12

Tom van Blarcom

Chief Tech/Sci/R&D Officer

2022-07-31

Composition of the Board of Directors: Kyverna Therapeutics, Inc.

Director

CommitteesSince

Christi Shaw

59 year

Audit Committee	2023-12-13
Governance Committee	2023-12-13
Nominating Committee	2023-12-13

Ian Clark

64 year

Compensation Committee	2018-12-31
Governance Committee	2024-07-07
Nominating Committee	2024-07-07
Governance Committee Chair	2020-07-31
Nominating Committee Chair	2020-07-31
Audit Committee	2025-07-31

Beth Seidenberg

67 year

Executive Committee
Compensation Committee Chair	2018-08-31
Governance Committee	2018-08-31
Nominating Committee	2018-08-31
Audit Committee	2016-05-31

Dan Spiegelman

68 year

Governance Committee	2024-06-10
Nominating Committee	2024-06-10
Audit Committee Chair	2024-06-10
Compensation Committee	2020-11-17

Fred Cohen

69 year

Compensation Committee	2013-12-31
HR Committee	2013-12-31

Mert Aktar

47 year

Audit Committee

2024-10-19

Warner Biddle

59 year

Director/Board Member

2024-09-15

Latest Appointments: Kyverna Therapeutics, Inc.

Feb. 24	Kyverna Therapeutics, Inc. Announces Board and Committee Changes	CI
Feb. 24	Kyverna Therapeutics appoints biotech leaders Sravan Emany and Andrew Miller to board of directors	RE
Feb. 03	Kyverna Therapeutics, Inc. Announces Resignation Karen Walker as Chief Technology Officer, Effective February 9, 2026	CI
Feb. 03	Kyverna Therapeutics, Inc. Appoints Mayo Pujols as Chief Technology Officer, Effective February 9, 2026	CI
Jan. 12	Kyverna Therapeutics, Inc. Appoints Christi Shaw as Executive Chairperson of the Board, Effective January 12, 2026	CI
25-09-25	Kyverna Therapeutics, Inc. Announces Board and Committee Changes	CI
25-06-30	Kyverna Therapeutics Names Marc Grasso as CFO	MT

More news

Former Officers and Directors: Kyverna Therapeutics, Inc.

Insider

Positions held

SinceUntil

Karen Walker

Chief Tech/Sci/R&D Officer

2021-08-31

2026-02-08

Steve Liapis

Director/Board Member	2022-10-31	2025-09-29
Independent Dir/Board Member	2022-10-31	2025-09-29

Ryan Jones

Director of Finance/CFO

2022-12-31

2025-06-29

Benjamin Dewees

General Counsel

2022-12-31

2025-01-31

Dominic Borie

Director/Board Member	2019-12-31	2022-10-12
Chief Executive Officer	2019-12-31	2022-10-12
Chief Tech/Sci/R&D Officer	2022-10-12	2025-01-21
President	2019-12-31	2022-10-12

James Chung

Chief Tech/Sci/R&D Officer

2021-03-31

2024-11-21

Peter Maag

Director/Board Member	2022-10-12	2024-09-12
Chief Executive Officer	2022-10-12	2024-09-12

Brian Kotzin

Director/Board Member	2019-07-31	2024-09-12
Independent Dir/Board Member	2019-07-31	2024-09-12

Ashoo Gupta

Comptroller/Controller/Auditor

2023-08-31

2024-05-31

Portia Serame

Human Resources Officer

2023-07-31

2023-12-31

George A. Thampy

Investor Relations Contact

2023-09-30

Jeffrey Greve

Chief Tech/Sci/R&D Officer	2018-04-30	2022-08-22
Founder	2018-04-30	2022-08-22

Peter Emtage

Director/Board Member

2022-01-25

Mark Genovese

Director/Board Member

2022-01-25

Desmond Padhi

Director/Board Member

2022-01-25

Shaan Gandhi

Director/Board Member

2022-01-25

Stefan Vitorovic

Director/Board Member

2022-01-25

Heba Nowyhed

Director/Board Member

2022-01-25

Age distribution of managers

Parity Men Women

Male	11
Female	3

Of which Executive Committee

Male	5
Female	1

Of which Directors

Male	6
Female	1

Revisions

Recommandations analystes

Évolution recommandations analystes 1 an

Évolution recommandations analystes 4 mois

Objectif analystes

Évolution objectif analystes 1 an

Évolution objectif analystes 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

Kyverna Therapeutics, Inc. is a patient-centered, clinical-stage biopharmaceutical company. The Company is focused on developing cell therapies for patients suffering from autoimmune diseases. The Company's lead program, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor (CAR). It intends to develop KYV-101 in two areas of autoimmune disease: rheumatology and neurology. Its initial rheumatology development focus is on lupus nephritis, and systemic sclerosis. It is also actively developing an allogeneic, off-the-shelf approach to further broaden patient access. Its research-stage programs are focused on developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease (IBD), which includes Crohnâ€™s disease and ulcerative colitis, and extend beyond CD19 CAR-T approaches, including regulatory T cells, or T-regs, and novel humanized CAR constructs developed by it for use in autoimmune diseases.

Employees

129

Sector

Biotechnology & Medical Research

More about the company